Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
285.4 SEK | +0.71% | +8.60% | +6.89% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 4.53 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.89% | 8.81B | B+ | ||
-3.45% | 87.17B | A- | ||
+2.76% | 40.1B | A- | ||
-16.98% | 31.38B | B- | ||
+57.86% | 25.12B | A | ||
-16.24% | 15.59B | C | ||
-9.12% | 12B | D+ | ||
-42.56% | 11.8B | B | ||
-17.10% | 11.8B | B- | ||
-10.53% | 8.24B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SOBI Stock
- Ratings Swedish Orphan Biovitrum AB